Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In the past year, we have witnessed a flurry of debates in the biomedical arena, from the uproar surrounding price gouging to the ethical hand-wringing over the use of CRISPR-Cas9 technology for genome editing. Beyond these topics, 2015 also made news with vaccine mandates, epigenetic mapping and even an accidental shipment of anthrax.
This year's newsworthy drugs made strides against cancer, heart disease and more. Some drugs made headlines for their inability to succeed in clinical trials, and others are still waiting, stuck in limbo, for a chance to move forward in the pipeline. Here is a look at a few of them.
Aging is receiving more attention as a risk factor for human disease. With the correct modeling of human heterogeneity and consideration of the environmental factors involved in the aging process, we may be able to delay the onset of human disease.
Our list of newsmakers this year includes some standout personalities, from a price-hiking, former hedge fund manager to a persistent and now-well-recognized immunotherapy advocate.
This year saw a whirlwind of insights gleaned into topics ranging from heart cell proliferation to organoid modeling. Here are a few of the research papers detailing some of these intriguing discoveries.
Journals can and should ensure that they erect no barriers to fast and wide sharing of critical data during major public health emergencies. But funders and scientists must also play a part.
The Canadian Institutes of Health Research (CIHR) recently terminated its MD/PhD training program without clear alternative funding in place. This misguided decision must urgently be reversed, as it has the potential to diminish a unique pool of graduates at the forefront of translational research.